RE:RE:2.50$ is stickyLeast we forget that they now have 3-4 very large shareholders, 1 of whom was diluted already, that will want a smart solution and not more dilution. You have Soleus, AIGH, Morgan Stanley and Stewardship. I'm not sure if the other two ONO guys are still in (Armitage and Stone Hill or something like that). I think THTX would find a lot more push back on timing and terms. Given they could have a reportable efficacy scenario (even if just single or small number) you'd think they would wait through the summer and allow the trial to play out more. You could easily raise what you want if you get Breakthrough.
As a reminder, BTD is really when Immunomedics (Trodelvy) turned and never looked back. It went from $1.50 to $4+ in the Phase 1, but fell back to the $2-3 level and bounced around as Phase 1 ended. They started phase 2 and got BTD and that's when it went from $4 to $40+, eventually being taken out at $90.
jeffm34 wrote: Something like 20M shares at $2.50 and another $50M in debt perhaps?
Biobob wrote: Maybe it's OO no. 2 pricing.. lol...